LEXEO Therapeutics, Inc., a clinical stage genetic medicine company, entered an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Under...
CureVac N.V., a global biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), and The University of Texas MD Anderson Cancer Center entered a co-development and licensing agreement to develop novel mRNA-based cancer...
Batavia Biosciences, a contract development and manufacturing organization, has partnered with ChromaTan, Inc. for the development and integration of BioRMB (formerly known as Continuous Countercurrent Tangential Chromatography or CCTC) technology into Batavia’s AAV...